CN110339203A - 用于改变端粒酶介导的端粒的巯基嘌呤核糖核苷类似物 - Google Patents

用于改变端粒酶介导的端粒的巯基嘌呤核糖核苷类似物 Download PDF

Info

Publication number
CN110339203A
CN110339203A CN201910445731.XA CN201910445731A CN110339203A CN 110339203 A CN110339203 A CN 110339203A CN 201910445731 A CN201910445731 A CN 201910445731A CN 110339203 A CN110339203 A CN 110339203A
Authority
CN
China
Prior art keywords
pharmaceutical composition
thio
composition
cells
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910445731.XA
Other languages
English (en)
Chinese (zh)
Inventor
J.W.谢
S.M.格里亚兹诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAXAS SYSTEM, University of, Regents of
Original Assignee
TAXAS SYSTEM, University of, Regents of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAXAS SYSTEM, University of, Regents of filed Critical TAXAS SYSTEM, University of, Regents of
Publication of CN110339203A publication Critical patent/CN110339203A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biochemistry (AREA)
CN201910445731.XA 2013-04-08 2014-04-08 用于改变端粒酶介导的端粒的巯基嘌呤核糖核苷类似物 Pending CN110339203A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361809575P 2013-04-08 2013-04-08
US61/809575 2013-04-08
CN201480032692.6A CN105338987A (zh) 2013-04-08 2014-04-08 用于改变端粒酶介导的端粒的巯基嘌呤核糖核苷类似物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480032692.6A Division CN105338987A (zh) 2013-04-08 2014-04-08 用于改变端粒酶介导的端粒的巯基嘌呤核糖核苷类似物

Publications (1)

Publication Number Publication Date
CN110339203A true CN110339203A (zh) 2019-10-18

Family

ID=50819958

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910445731.XA Pending CN110339203A (zh) 2013-04-08 2014-04-08 用于改变端粒酶介导的端粒的巯基嘌呤核糖核苷类似物
CN201480032692.6A Pending CN105338987A (zh) 2013-04-08 2014-04-08 用于改变端粒酶介导的端粒的巯基嘌呤核糖核苷类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480032692.6A Pending CN105338987A (zh) 2013-04-08 2014-04-08 用于改变端粒酶介导的端粒的巯基嘌呤核糖核苷类似物

Country Status (17)

Country Link
US (1) US10463685B2 (enExample)
EP (2) EP2983675A2 (enExample)
JP (1) JP6525956B2 (enExample)
KR (1) KR20150143587A (enExample)
CN (2) CN110339203A (enExample)
AU (1) AU2014251093B2 (enExample)
BR (1) BR112015025206A2 (enExample)
CA (1) CA2907924C (enExample)
ES (1) ES3038057T3 (enExample)
HK (1) HK1219418A1 (enExample)
HU (1) HUE072426T2 (enExample)
MX (1) MX387008B (enExample)
NZ (1) NZ713498A (enExample)
PL (1) PL3682888T3 (enExample)
RU (1) RU2713555C2 (enExample)
SG (2) SG10202002556QA (enExample)
WO (1) WO2014168947A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017165675A1 (en) * 2016-03-24 2017-09-28 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
EP3463370A4 (en) * 2016-05-27 2020-04-08 The Board of Regents of The University of Texas System 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE-DEPENDENT TELOMER DYS FUNCTION AND CELL DEATH IN THERAPY-RESISTANT CANCER CELL
WO2019183482A1 (en) * 2018-03-22 2019-09-26 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
AU2019208197B2 (en) 2018-07-31 2025-05-29 Howmedica Osteonics Corp. Fixation devices and prostheses for soft tissue connection to the same
US11535645B2 (en) 2018-10-17 2022-12-27 Xibin Liao 6-mercaptopurine nucleoside analogues
USD1046142S1 (en) 2019-07-24 2024-10-08 Howmedica Osteonics Corp. Proximal tibial prosthesis
CN112898292A (zh) 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
IL296403A (en) 2020-03-13 2022-11-01 Univ Texas Sequential cancer treatment using 6-thio-dg, checkpoint inhibitors and radiation therapy
WO2024188308A1 (zh) * 2023-03-14 2024-09-19 上海华汇拓医药科技有限公司 一类核苷类似物及其应用
WO2024188302A1 (zh) * 2023-03-14 2024-09-19 上海华汇拓医药科技有限公司 一类靶向端粒酶的核苷类似物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100323979A1 (en) * 2009-06-16 2010-12-23 Weis-Amon Angelika B Methods and compositions for inhibiting proliferation of aneuploid cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57209226A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
CA2100655C (en) 1991-02-08 2004-02-03 Reid W. Von Borstel Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
WO2006114064A2 (en) 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
CN101220071B (zh) * 2008-01-17 2011-04-06 南京长澳医药科技有限公司 稳定的6-甲氧基-2’,3’-双脱氧鸟嘌呤核苷及其制备方法和包含它的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100323979A1 (en) * 2009-06-16 2010-12-23 Weis-Amon Angelika B Methods and compositions for inhibiting proliferation of aneuploid cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G.A. LEPAGE: "Manipulation of DNA synthesis in normal and neoplastic tissues with drugs", 《ADVANCES IN ENZYME REGULATION》 *
SUSAN W. TENDIAN等: "Interaction of Deoxyguanosine Nucleotide Analogs with Human Telomerase", 《MOLECULAR PHARMACOLOGY》 *
V N VISWANADHAN等: "Analysis of the in Vitro Antitumor Activity of Novel Purine-6-sulfenamide,-sulfinamide, and -sulfonamide Nucleosides and Certain Related Compounds Using a Computer-Aided Receptor Modeling Procedure", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
EP2983675A2 (en) 2016-02-17
NZ732228A (en) 2020-11-27
SG10202002556QA (en) 2020-04-29
CA2907924A1 (en) 2014-10-16
JP2016516773A (ja) 2016-06-09
EP3682888A1 (en) 2020-07-22
CA2907924C (en) 2022-10-25
AU2014251093B2 (en) 2017-06-15
US10463685B2 (en) 2019-11-05
PL3682888T3 (pl) 2025-09-22
RU2713555C2 (ru) 2020-02-05
RU2015147555A (ru) 2017-05-15
HK1219418A1 (zh) 2017-04-07
ES3038057T3 (en) 2025-10-09
BR112015025206A2 (pt) 2017-07-18
AU2014251093A1 (en) 2015-10-15
MX2015014159A (es) 2016-06-21
NZ713498A (en) 2017-07-28
KR20150143587A (ko) 2015-12-23
MX387008B (es) 2025-03-19
WO2014168947A9 (en) 2014-12-31
US20140303239A1 (en) 2014-10-09
CN105338987A (zh) 2016-02-17
EP3682888B1 (en) 2025-06-11
WO2014168947A3 (en) 2015-02-19
SG11201508336TA (en) 2015-11-27
HUE072426T2 (hu) 2025-11-28
JP6525956B2 (ja) 2019-06-05
WO2014168947A2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
CA2907924C (en) Telomerase mediated telomere altering compounds
JP2015519057A (ja) Ｐｔｅｎ発現を調節するための組成物及び方法
JP2015518713A (ja) Ｕｔｒｎ発現を調節するための組成物及び方法
JP2015523853A (ja) Ａｔｐ２ａ２発現を調節するための組成物及び方法
JP2015518714A (ja) 遺伝子発現を調節するための組成物及び方法
CN104884090A (zh) 细胞凋亡诱导剂
EA023793B1 (ru) Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии
US20190382433A1 (en) Glycolipids and pharmaceutical compositions thereof for use in therapy
CN113543789A (zh) 用于癌症治疗的脱氧胞苷或尿苷衍生物
CN105744958B (zh) 新颖医药组成物及其用途
NZ732228B2 (en) Telomerase mediated telomere altering compounds
WO2020218494A1 (ja) ｍｉＲ３０２核酸改変体
US20250136633A1 (en) Telomere-targeting phosphatidyl-thio conjugates
US20240115594A1 (en) Dinucleotides and their use in treating cancer
US9617538B2 (en) Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells
JP2024503513A (ja) がんを処置するための併用療法スケジュール
WO2025015018A1 (en) Conditional proteolysis gene silencing targeting chimera and methods of use thereof
KR20130097585A (ko) 암치료 보조용 조성물
JP2006206607A (ja) 癌細胞内ヌクレアーゼ活性化剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191018